Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study

Tuomas Kiviniemi, K.e. Juhani Airaksinen, Andrea Rubboli, Fausto Biancari, Josè Valencia, Gregory Y.h. Lip, Pasi P. Karjalainen, Michael Weber, Mika Laine, Paulus Kirchhof, Axel Schlitt

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)
782 Downloads (Pure)

Abstract

Background
Recent reports have provided evidence that bridging therapy with low-molecular-weight heparin (LMWH) may increase bleeding complications in patients with atrial fibrillation (AF) on oral anticoagulation undergoing percutaneous coronary intervention (PCI). We sought to assess mid-term bleeding and thromboembolic events in patients from the AFCAS registry discharged on triple therapy (TT).

Methods
AFCAS is a multicenter, prospective registry enrolling patients with AF undergoing PCI. The primary endpoints were: 1) bleeding complications as defined by the bleeding academic research criteria (BARC); 2) a composite of cardiac and cerebrovascular events (MACCE) at 3 and 12 month follow-ups.

Results
Altogether 663 out of 929 consecutive patients were discharged on TT, either on oral vitamin K antagonist (VKA-TT) (n = 498) or bridging LMWH-TT (n = 165). Patients on LMWH-TT had more often diabetes, heart failure, and hypertension compared to those on VKA-TT. The rates of major bleeding events (BARC ≥ 3) (11.5% vs. 6.0%, p = 0.03) as well as MACCE (11.5% vs. 5.0%, p = 0.006) were higher in the LMWH-TT group compared to VKA-TT group at 3 months follow-up. In a Cox multivariate regression model and propensity-score matched analysis LMWH-TT increased the risk for major BARC bleeding events at 3 and 12 month follow-ups.

Conclusions
In this large, prospective, real-world population of patients with AF undergoing PCI patients discharged on LMWH-TT had a significantly higher risk for major bleeds in comparison to patients discharged on VKA-TT. LMWH-bridging therapy appeared harmful in this subset of patient on oral anticoagulation.
Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalInternational Journal of Cardiology
Volume183
Early online date27 Jan 2015
DOIs
Publication statusPublished - 15 Mar 2015

Fingerprint

Dive into the research topics of 'Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study'. Together they form a unique fingerprint.

Cite this